Abstract: Coated pharmaceutical packages are disclosed. The coated pharmaceutical packages may include a glass body formed from one of a borosilicate glass composition that meets Type 1 criteria according to USP <660> or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A low-friction coating may be positioned on at least a portion of the first surface of the glass body the low-friction coating may include a polymer and a coupling agent disposed between the polymer and the first surface of the glass body. A coefficient of friction of the portion of the coated pharmaceutical package with the low-friction coating is at least 20% less than a coefficient of friction of a surface of an uncoated pharmaceutical package formed from the same glass composition.

Abstract: Coated pharmaceutical packages may comprise a glass body formed from a borosilicate glass composition having a Type 1 chemical durability according to USP 660, the glass body having an interior surface and an exterior surface and a wall extending therebetween. A low-friction thermally stable coating having a thickness of ?1 ?m may be positioned on at least a portion of the exterior surface. The low-friction coating may comprise a silane. The portion of the exterior surface of the coated pharmaceutical package may have a coefficient of friction that is at least 20% less than an uncoated pharmaceutical package formed from the same borosilicate glass composition.

Abstract: Embodiments of a vehicle interior system are disclosed. In one or more embodiments, the system includes a base with a curved surface, and a display or touch panel disposed on the curved surface. The display includes a cold-bent glass substrate with a thickness of 1.5 mm or less and a first radius of curvature of 20 mm or greater, and a display module and/or touch panel attached to the glass substrate having a second radius of curvature that is within 10% of the first radius of curvature. Methods for forming such systems are also disclosed.

Abstract: Coated pharmaceutical packages are disclosed. The coated pharmaceutical packages may include a glass body comprising a first surface and a second surface opposite the first surface. The glass body may be a glass container formed from a borosilicate glass composition and the first surface is an exterior surface of the glass container. A low-friction coating may be positioned on at least a portion of the first surface of the glass body. In embodiments, the low-friction coating may be a fluoropolymer.

Abstract: Embodiments of a vehicle interior system are disclosed. In one or more embodiments, the system includes a base with a curved surface, and a display or touch panel disposed on the curved surface. The display includes a cold-bent glass substrate with a thickness of 1.5 mm or less and a first radius of curvature of 20 mm or greater, and a display module and/or touch panel attached to the glass substrate having a second radius of curvature that is within 10% of the first radius of curvature. Methods for forming such systems are also disclosed.

Abstract: Coated glass pharmaceutical packages are disclosed. According to embodiments, a coated glass pharmaceutical package may include a glass container formed from one of a borosilicate glass composition that meets Type 1 criteria according to USP <660> or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A low-friction coating may be bonded to the exterior surface of the glass container. The low-friction coating may include a polymer. The exterior surface of the glass container with the low-friction coating may have a coefficient of friction of less than or equal to 0.7. The coated glass pharmaceutical package may be thermally stable after depyrogenation in air at a temperature of at least about 260° C. for 30 minutes.

Abstract: According to one embodiment, a glass article may include a glass body having a first surface and a second surface opposite the first surface. The first surface of the glass body may be etched to a depth less than or equal to about 25% of the maximum initial flaw depth Ai of a flaw population present in the first surface. The flaw population of the first surface is etched to selectively remove material adjacent to each flaw of the flaw population along the maximum initial flaw depth Ai. When the glass article is under uniaxial compressive loading, at least a portion of the first surface is in tension and a uniaxial compressive strength of the glass article is greater than or equal to 90% of a uniaxial compressive strength of a flaw-free glass article.

Abstract: According to one embodiment, a glass article may include a glass body having a first surface and a second surface opposite the first surface. The first surface and the second surface each have a radius of curvature. The first surface of the glass body comprises a flaw population extending from the first surface into a thickness of the glass body with a maximum initial flaw depth Ai. The first surface of the glass body may be etched to a depth less than or equal to about 25% of the maximum initial flaw depth Ai of the flaw population present in the first surface. When the glass article is under uniaxial compressive loading, at least a portion of the first surface is in tension and a uniaxial compressive strength of the glass article is greater than or equal to 90% of a uniaxial compressive strength of a flaw-free glass article.

Abstract: A glass-based article having an amorphous phase and a crystalline phase, and a first surface and a second surface opposing the first surface thereby defining a thickness (t) of the glass-based article. The glass-based article having a stress profile with a surface compressive stress (CS) and a maximum central tension (CT). The maximum CT is greater than or equal to 50 MPa and less than or equal to 200 MPa and is positioned within the glass-based article at a range from greater than or equal to 0.4·t and less than or equal to 0.6·t. The surface CS is greater than or equal to 200 MPa and less than or equal to 500 MPa, and a depth of compression (DOC) is from greater than or equal to 0.14·t and less than or equal to 0.25·t.

Abstract: A glass container for storing pharmaceutical formulations may include a glass body formed from a Type IA or Type IB glass composition according to ASTM Standard E438-92(2011). The glass body may include a wall portion with an inner surface and an outer surface, a heel portion and a floor portion, wherein the inner surface of the glass container is formed by the inner surface of the glass body. The glass body may include at least a class A2 base resistance or better according to ISO 695, at least a type HGB2 hydrolytic resistance or better according to ISO 719 and Type 1 chemical durability according to USP <660>. The glass container does not comprise a boron-rich layer on the inner surface of the glass body in as formed condition.

Abstract: Embodiments of the present disclosure are directed to coated glass articles which reduce glass particle formation caused by glass to glass contact in pharmaceutical glass filling lines.

Abstract: Glass pharmaceutical packages comprising glass containers are disclosed. In embodiments, a coated glass pharmaceutical package includes a glass container formed from one of a borosilicate glass composition that meets Type 1 criteria according to USP <660> or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A lubricous coating may be positioned on at least a portion of the exterior surface of the glass container. The portion of the coated glass pharmaceutical package with the lubricous coating has a coefficient of friction that is at least 20% less than an uncoated glass container formed from the same glass composition. A horizontal compression strength of the portion of the coated glass pharmaceutical package with the lubricous coating may be at least 10% greater than an uncoated glass container formed from the same glass composition.

Abstract: A delamination resistant glass pharmaceutical container may include a glass body comprising a borosilicate glass having a Type 1 chemical durability according to USP <660>. At least an inner surface of the glass body may have a delamination factor less than or equal to 10. A thermally stable coating may be positioned around at least a portion of the outer surface of the glass body. The thermally stable coating may be an outermost coating on the outer surface of the glass body and the outer surface of the glass body with the thermally stable coating has a coefficient of friction less than or equal to 0.7. The thermally stable coating comprising at least one of a metal nitride coating, a metal oxide coating, a metal sulfide coating, SiO2, diamond-like carbon, graphene, and a carbide coating.

Abstract: Disclosed herein are delamination resistant glass pharmaceutical containers which may include an aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to ISO 720-1985 testing standard. The glass containers may also have a compressive stress layer with a depth of layer of greater than 25 ?m. A surface compressive stress of the glass containers may be greater than or equal to 350 MPa. The delamination resistant glass pharmaceutical containers may be ion exchange strengthened and the ion exchange strengthening may include treating the delamination resistant glass pharmaceutical container in a molten salt bath for a time less than or equal to 5 hours at a temperature less than or equal to 450° C.

Abstract: According to embodiments, a method of making a coated pharmaceutical container, may include: forming a glass tube; forming the glass tube into a pharmaceutical container comprising an interior surface and an exterior surface; and applying a coating to the exterior surface. The coating may have a coefficient of friction less than or equal to 0.7 relative to a second pharmaceutical container when tested in a vial-on-vial testing jig under a normal load of 30 N. The coated pharmaceutical container may be thermally stable after depyrogenation at a temperature of at least 260° C. for 30 minutes in air.

Abstract: Embodiments of the present disclosure are directed to coated glass articles which reduce glass particle formation caused by glass to glass contact in pharmaceutical glass filling lines.

Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may have a surface compressive stress of at least 350 MPa.

Abstract: Embodiments of a vehicle interior system are disclosed. In one or more embodiments, the system includes a base with a curved surface, and a display or touch panel disposed on the curved surface. The display includes a cold-bent glass substrate with a thickness of 1.5 mm or less and a first radius of curvature of 20 mm or greater, and a display module and/or touch panel attached to the glass substrate having a second radius of curvature that is within 10% of the first radius of curvature. Methods for forming such systems are also disclosed.

Abstract: Embodiments of this disclosure pertain to a strengthened glass article including a first surface and a second surface opposing the first surface defining a thickness (t) of about less than about 1.1 mm, a compressive stress layer extending from the first surface to a depth of compression (DOC) of about 0.1·t or greater, such that when the glass article fracture, it breaks into a plurality of fragments having an aspect ratio of about 5 or less. In some embodiments, the glass article exhibits an equibiaxial flexural strength of about 20 kgf or greater, after being abraded with 90-grit SiC particles at a pressure of 25 psi for 5 seconds. Devices incorporating the glass articles described herein and methods for making the same are also disclosed.

Abstract: A coated glass article and methods for producing the same are provided herein. The coated glass article includes a glass body having a first surface and a second surface opposite the first surface, wherein the first surface is an exterior surface of the glass body, and a damage-resistant coating formed by atomic layer deposition, the damage-resistant coating being disposed on at least a portion of the first surface of the glass body.